You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國藥控股(01099.HK):1-2月歸母淨利潤下降約50% 一季度業績或大幅下降
格隆匯 03-08 19:07

格隆匯3月8日丨國藥控股(01099.HK)發佈公告,由於“新型冠狀病毒肺炎”疫情爆發,2020年1月下旬起,政府採取了嚴格防控手段,包括延長假期、集中全國醫療資源於重點地區抗擊疫情、減少人員流動和聚集等措施以遏制疫情蔓延、保護人民生命安全。國內的部分社會生產經營,包括醫療機構及零售藥店的正常藥品銷售在此背景下相應受到影響。另一方面,自2019年末起,藥品集中帶量採購政策實施範圍逐步擴大至全國,而在疫情環境下,集團在與供應商確認返利及產品降價補償等方面也受到影響。鑑於上述因素,集團2020年1至2月份的銷售收入增速明顯下降,毛利率水準也有所下降,截至2020年2月29日止兩個月,歸屬於母公司所有者的淨利潤較去年同期下降約為50%左右。

基於集團現有的財務和經營信息,以及外部市場環境和疫情所處階段,董事會預計,集團截至2020年3月31日止一季度業績可能出現較大幅度同比下降。

公告表示,儘管此次疫情對行業上下游及集團經營帶來較大直接和間接影響,但這些影響是暫時的,相信隨着疫情逐漸結束,社會生產和經營迴歸正常,有關降價補償,銷售返利也將恢復常態,集團相關財務指標會逐步有所恢復。

此外,中國醫藥流通行業長期向好的發展趨勢未變,集團業務基本面未變,隨着市場優勢地位的進一步提升,加之內部持續推進的戰略與業務轉型升級,董事會對集團保持長期穩健發展仍保持堅定信心。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account